Valuation: BenevolentAI S.A.

Market Cap 8.34M 11.22M 9.75M 9.08M 15.74M 1.07B 15.99M 107M 42M 533M 42.14M 41.22M 1.79B P/E 2023
-1.75x
P/E 2024 -
Enterprise Value -18.83M -25.35M -22.03M -20.51M -35.56M -2.42B -36.11M -242M -94.88M -1.2B -95.19M -93.1M -4.04B EV / Sales 2023
5.72x
EV / Sales 2024 2.15x
Free-Float
59.54%
Yield 2023 *
-
Yield 2024 -
3 years 0.07
Extreme 0.07
2.66
5 years 0.07
Extreme 0.07
10
10 years 0.07
Extreme 0.07
10
Manager TitleAgeSince
Chief Operating Officer 50 2014-01-31
Director of Finance/CFO - 2024-10-15
Chief Tech/Sci/R&D Officer - 2024-03-31
Director TitleAgeSince
Director/Board Member 70 2020-06-30
Chairman 70 2024-05-01
Director/Board Member 58 2013-10-31
Date Insider Type Main position Quantity % Market Cap.
2/9/24 Buy

Director

10,000 0.0070%
2/9/24 Buy

Director

2,066 0.0014%
2/9/24 Buy

Director

20,000 0.0140%
Change 5-day change 1-year change 3-year change Capi.($)
-14.74%-.--%-.--%-93.91% 11.59M
-1.40%+2.59%-1.71%+11.28% 48.53B
-2.41%-0.90%+411.96%+495.33% 39.87B
-1.16%+12.96%+28.81%+7.25% 38.68B
-1.88%-3.03%+5.69%+53.00% 35.13B
-1.74%+5.12%+14.44%+41.77% 29.79B
-0.21%-4.04%+36.40%+125.75% 16.11B
-2.85%-3.92% - - 16.08B
-0.64%+2.65%+3.40%+13.11% 13.61B
-1.19%-1.32%-1.73%-34.37% 12.62B
Average -2.82%-2.01%+55.25%+68.80% 25.04B
Weighted average by Cap. -1.60%+2.03%+79.78%+108.60%

Financials

2023 2024
Net sales 7.33M 9.87M 8.58M 7.98M 13.84M 942M 14.06M 94.12M 36.94M 469M 37.06M 36.25M 1.57B 5.24M 7.06M 6.13M 5.71M 9.9M 674M 10.05M 67.3M 26.41M 335M 26.5M 25.92M 1.12B
Net income -63.32M -85.23M -74.09M -68.96M -120M -8.14B -121M -813M -319M -4.05B -320M -313M -13.58B -71.82M -96.68M -84.04M -78.23M -136M -9.23B -138M -922M -362M -4.59B -363M -355M -15.41B
Net Debt -68.16M -91.75M -79.76M -74.24M -129M -8.76B -131M -875M -343M -4.36B -345M -337M -14.62B -27.17M -36.57M -31.79M -29.59M -51.3M -3.49B -52.1M -349M -137M -1.74B -137M -134M -5.83B
Logo BenevolentAI S.A.
BenevolentAI SA is engaged in creating and applying artificial intelligence (AI) and machine learning in drug discovery. The Company designs its technology to enable scientists to better understand the development of disease mechanisms, discover drug targets and make decisions. It serves patients by leveraging its proprietary and validated Benevolent Platform that integrates AI and science to uncover new biology, predict novel targets and develop drugs for complex diseases. The Benevolent Platform integrates technology, processes, and humans for faster research and development success. Its pipeline includes BEN-8744, BEN-28010, BEN-34712, Parkinson's disease, and Fibrosis. BEN-8744 is developed for the treatment of an ulcerative colitis. The Company provides scientists with a view of disease biology by integrating across all the domains and diverse data types, including omics, molecules, experimental data, literature, pathology, and biological systems.
Employees
173